US equities |
NVDA $238.90 ▲+2.12% SPCX $171.09 ▲+7.63% MU $1,063.96 ▼-1.02% TSLA $378.73 ▲+2.20% WBD $30.95 ▲+0.03% MSFT $525.18 ▲+1.48% AAPL $332.89 ▼-0.24% META $741.90 ▲+1.90%
FinancialContent

Cellectis S.A. - American Depositary Shares (NQ:CLLS)

1.410 -0.020 (-1.40%)
Delayed Quote Updated: 4:00 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cellectis S.A. - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Cellectis Reports Results from Shareholders Meeting Held on June 26, 2025
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis’ Annual Shareholders General Meeting to be Held on June 26, 2025
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis Reports Financial Results for the First Quarter 2025
From Cellectis Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For May 12, 2025 ↗
 
Via Benzinga
News headline image
Cellectis to Report First Quarter Financial Results on May 12, 2025
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis Presents Non-Viral Gene Editing and Base Editing Innovation at the ASGCT Annual Meeting
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis Charts Course for 2025 With Boost From AstraZeneca Deal
Cellectis, backed by AstraZeneca funding and a multi-year cash runway, is advancing its prioritized allogeneic CAR-T pipeline toward pivotal 2025 milestones. 
Via MarketBeat
News headline image
The market is filled with gapping stocks in Friday's session. ↗
Today's session on Friday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Rubrik Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2024 and Provides a Business Update
From Cellectis Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For March 13, 2025 ↗
 
Via Benzinga
News headline image
Cellectis to Report Fourth Quarter and Full Year 2024 Financial Results on March 13, 2025
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis Presents ‘Smart CAR T’ Strategy to Enhance Efficacy Against Solid Tumors at AACR-IO 2025
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis announces the drawdown of the third tranche of €5 million under the credit facility agreement entered with the European Investment Bank (EIB)
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis Presents Multiple Strategies to Enhance CAR T-cell Efficacy in Solid Tumors at the SITC Annual Meeting
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis Provides Business Updates and Financial Results for Third Quarter 2024
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis to Report Third Quarter 2024 Financial Results on November 4, 2024
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis to Present Data on TALE-Base Editors and Non-Viral Gene Therapy at the ESGCT 31st Annual Congress
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis Presents Pre-Clinical Evidence of MUC1 CAR T-cells Reducing Triple-Negative Breast Cancer While Preserving Safety
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Recalcitrant Solid Tumors
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis Appoints Dr. Adrian Kilcoyne as Chief Medical Officer
From Cellectis Inc.
Via GlobeNewswire
News headline image
CLLS Stock Earnings: Cellectis Beats EPS, Beats Revenue for Q2 2024 ↗
CLLS stock results show that Cellectis beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Cellectis Provides Financial Results for the Second Quarter 2024
From Cellectis Inc.
Via GlobeNewswire
News headline image
FDA Grants Orphan Drug Designation to Cellectis’ CLLS52 (alemtuzumab) For ALL Treatment
From Cellectis Inc.
Via GlobeNewswire
News headline image
FDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis’ UCART22 product candidate for Acute Lymphoblastic Leukemia (ALL) Treatment
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis Reports Results from Shareholders Meeting Held on June 28, 2024
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base Editing
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications
From Cellectis Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >